The short version
- Why people research itTendon, gut and soft-tissue repair — the BPC-157 peptide as an arginate salt, sold on shelf stability rather than a different mechanism.
- What the evidence isNo human trial of PDA exists, and none of BPC-157 either.
- What to watchA new lump or a mole that changes.
How PDA works
Start with what an arginate salt is, because that is the only thing distinguishing this page from the BPC-157 page, and the answer is smaller than the marketing suggests. A peptide with free carboxyl groups can be isolated as a salt with any suitable counter-ion.
So what CAN a counter-ion change? Three real things, all physical. The hygroscopicity and shelf stability of the lyophilized powder; and the solubility profile.
The sequence, and therefore the mechanism, is the same: VEGFR2 and nitric-oxide signaling driving angiogenesis, with the growth-factor upregulation behind the tendon, gut, muscle and nerve repair BPC-157 is known for. What the arginate counter-ion changes is the physical chemistry of the salt, and vendors market it as the more stable of the two. That is a formulation claim, not a potency claim: nobody has published a head-to-head of arginate against acetate in a living system.
- Injectable
On the goal map: Angiogenesis & cytoprotection (Heal an injury)
Research on PDA6 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Same peptide as BPC-157 - strong animal, heavy anecdotal, limited human. The arginate salt specifically has no comparative data at all.
Human clinical evidence
No human trial of PDA exists, and none of BPC-157 either. PDA is the same pentadecapeptide supplied as an arginate salt, so it inherits BPC-157's evidence position exactly: strong animal work, no completed randomized human efficacy trial, and a 2023 FDA move to bulk-substances category 2 that restricts compounding — a judgement about missing data, not a finding of harm.
No completed human trialNothing compares the two salts in a living system. The arginate is marketed as more stable. It is not a claim about what happens after injection, and no published work bridges the two.
Correlative data
The anecdotal record people cite for PDA is BPC-157's record, because the peptide is the same. That record is large and it is also the clearest case in the Vault of anecdote being a weak instrument: soft-tissue injuries and gut flares resolve on their own, so anything taken during recovery collects the credit.
PDA's own anecdotal history is short — it entered the research market recently, and reports specific to the arginate salt are too few and too new to separate from BPC-157's.
How the mechanism reads
Identical to BPC-157 by definition: VEGFR2 and nitric-oxide signaling driving angiogenesis, with growth-factor upregulation behind tendon, gut, muscle and nerve repair. A counter-ion changes the salt's physical chemistry, not the peptide's sequence or its receptor interactions.
MechanisticThe mechanistic argument FOR the arginate is pharmacokinetic — a more stable salt could mean more intact peptide surviving to the point of action. Plausible, unmeasured, and worth treating as a hypothesis rather than a feature.
Mechanistic
Sources
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology 2022 · PMID 36588717
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver 2020 · PMID 31158953
- Sikiric P, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World Journal of Gastroenterology 2022 · PMID 35125818
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel) 2023 · PMID 37242459
- Perovic D, et al. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. Current Issues in Molecular Biology 2022 · PMID 35678659
PDA safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Cancer history or a suspected tumor: pro-angiogenic VEGFR2 signaling can feed vessel growth to tumors.
- Proliferative eye disease such as diabetic retinopathy: VEGF-type signaling worsens abnormal vessel growth.
- Pregnancy: angiogenesis signaling has no safety data in gestation.
- Anticoagulant use: nitric-oxide effects on vessels and platelets could add to bleeding tendency.
What’s expected
- Less perceived joint, tendon or gut irritation over weeks, as the repair pathway is nudged.
- Mild dizziness or a warm feeling from nitric-oxide signaling.
- Little felt change, since evidence is mostly animal.
- No comparative data exist for the arginate salt itself.
Watch for
- A new lump or a mole that changes.
- Blurred vision or floaters.
- Fainting or a sharp drop in blood pressure.
- Redness, warmth or pus where it is applied.
Labs that tell you it’s working
- hs-CRP (C-Reactive Protein, High Sensitivity)
- ESR (Sed Rate, Westergren)
- Complete Blood Count (CBC) w/ Differential
- Comprehensive Metabolic Panel (CMP)
PDA is the BPC-157 sequence as an arginate salt, so VEGFR2 and nitric-oxide angiogenesis applies; the salt itself has no comparative data. PMID 20388964
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
PDA FAQ4 common questions
- Is PDA approved for human use?
- No. PDA is a research compound. No completed randomized human trial has given it yet.
- What is PDA researched for?
- Tendon, gut and soft-tissue repair — the BPC-157 peptide as an arginate salt, sold on shelf stability rather than a different mechanism.
- Which labs show whether it's doing anything?
- hs-CRP; ESR; Complete Blood Count; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for PDA: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




